GlassScriptPhysician profile
Harmon W Kelley
NPI 1083602957
$992.11
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $264 · 2021: $167 · 2022: $248.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $270.81 | 2019-2022 | |
| Pfizer INC. | $205.42 | 2019-2022 | |
| Hologic Sales and Service, LLC | $121.44 | 2019-2022 | |
| Astellas Pharma US INC | $116.35 | 2020-2022 | |
| Therapeuticsmd, INC. | $83.88 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $44.34 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $37.33 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $30.74 | 2019-2020 | |
| Lupin INC. | $20.65 | 2020 | |
| Duchesnay USA Incorporated | $17.38 | 2019 | |
| Medicem INC. | $16.91 | 2022 | |
| Roche Diagnostics Corporation | $13.52 | 2019 | |
| Coopersurgical, INC. | $13.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmon Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.